Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2026PharmaceuticalsOpen Access

Current Status of Drug Treatment of Cholangiocarcinoma—Updated Progress and Critical Limitations

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJennifer CillisCity Of Hope National Medical CenterCCCourtney ChenCedars-Sinai Medical CenterSDSupriya DeshpandeCity Of Hope National Medical Center

Discussion

Loading...

Member takes

Implication

This review discusses current drug treatments and new therapeutic approaches for cholangiocarcinoma, indicating ongoing challenges.

Key Points

  • This review aims to summarize the current state of drug treatments for cholangiocarcinoma and highlight limitations and advances in the field.
  • Review of standard drug treatment approaches for cholangiocarcinoma.
  • Analysis of landmark clinical trials including ABC-02, KEYNOTE-966, and TOPAZ-1.
  • Summary of recent findings on chemotherapy regimens and new therapeutic strategies.
  • Gemcitabine-cisplatin (GC) established as a standard first-line treatment for biliary cancers.
  • Emerging therapies such as CAR-T cells and oncolytic viruses show promise in preclinical studies.
  • Drug resistance mechanisms complicate treatment efficacy in cholangiocarcinoma patients.

Cite This Study

Cillis et al. (2026) studied this question.

synapsesocial.com/papers/69cd7ad45652765b073a841bhttps://doi.org/10.3390/ph19040554
View Full Paper
Ask AI
Bookmark
Share